Drug intelligence / Profile preview

virus inactivated plasma

Development stage
Unknown
Lead developer
Octapharma
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Virus inactivated plasma is human blood plasma that has undergone specific processes to render any contaminating viruses non-infectious. These processes are designed to reduce the risk of transmitting viral pathogens such as HIV, hepatitis A, B, and C, and parvoviruses through transfusion or use in cell culture and biomanufacturing. Common methods for viral inactivation include solvent/detergent treatment, pasteurization (heating), acidic pH treatment, ultraviolet (UV) irradiation (sometimes with riboflavin), and other validated chemical or physical procedures. Virus inactivated plasma is used both clinically for transfusion purposes and industrially as a supplement for cell culture media or component of bioassays. The process ensures safety by significantly reducing the risk of viral transmission while maintaining the functional properties of the plasma proteins[1][2][4].

Other names
virus-inactivated plasmapathogen-reduced plasma

Beyond the preview

Go deeper on virus inactivated plasma.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on virus inactivated plasma.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call